Yuji Hara, Ph.D.
Professor
Department of Integrative physiology
School of Pharmaceutical Sciences, University of Shizuoka
52-1 Yada,Suruga-ku,Shizuoka 422-8526, Japan
Phone: +81-54-264-5733; Fax: +81-54-264-5909
Email: yhara@u-shizuoka-ken.ac.jp
Education and professional positions:
Education
1997: B.S. and Pharmacist certification
Division of Bioorganic Chemistry, Laboratory of Bioactive Chemistry, Graduate School of
Pharmaceutical Sciences, Kyoto University, Japan.
1999: Master’s Course
Division of Bioorganic Chemistry, Laboratory of Bioactive Chemistry, Graduate School of
Pharmaceutical Sciences, Kyoto University, Japan
2002: Doctoral degree
Division of Molecular and Cellular Physiology, School of Life Science, The Graduate University for
Advanced Studies, Japan. (Thesis supervisor: Dr. Yasuo Mori)

Professional Activities
2002-2003 : Postdoctoral fellow
Division of Molecular and Cellular Physiology, Center for Integrative Bioscience, Japan (Mentor: Dr.
Yasuo Mori)
2003-2005 : Assistant Professor
Laboratory of Molecular Biology, Department of Synthetic Chemistry and Biological Chemistry,
Graduate School of Engineering, Kyoto University, Japan (Mentor: Dr. Yasuo Mori)
2005-2012: Postdoctoral fellow; 2012: Research associate
The Campbell laboratory, Howard Hughes Medical Institute, and the University of Iowa, Roy J. andLucille A. Carver College of Medicine, Department of Molecular Physiology & Biophysics (Mentor: Dr.
Kevin P. Campbell, Ph.D.)
2012-2013: Tenure-track associate professor
Tokyo Women’s Medical University Institute for Integrated Medical Sciences (TIIMS),
2013-2021: Associate professor
Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto
University2021-Present: Professor
Department of Integrative physiology, School of Pharmaceutical Sciences, University of Shizuoka

Scientific interests:
1. Roles of membrane proteins activated by physical force in muscle stem cells
2. Development of “mechano-medicine” for neuromuscular diseases
3. Role of phospholipid translocases in physiological systems

Selected publications:Tsuchiya M, *Hara Y, Okuda M, Itoh K, Nishioka R, Shiomi A, Nagao K, Mori M, Mori Y, Ikenouchi J, Suzuki
R, Tanaka M, Ohwada T, Aoki J, Kanagawa M, Toda T, Nagata Y, Matsuda R, Takayama Y, Tominaga M,*Umeda M. Cell surface flip-flop of phosphatidylserine is critical for PIEZO1-mediated myotube formation. Nat.
Commun., 9, 2049 (2018).
Okuma H, Saito F, Mitsui J, Hara Y, Hatanaka Y, Ikeda M, Shimizu T, Matsumura K, Shimizu J, Tsuji S, Sonoo
M. Tubular aggregate myopathy caused by a novel mutation in the cytoplasmic domain of STIM1. Neurology
Genet. e50 (2016).
Endo Y, Noguchi S, Hara Y, Hayashi YK, Motomura K, Miyatake S, Murakami N, Tanaka S, Yamashita S,Kizu R, Bamba M, Goto YI, Matsumoto N, Nonaka I, Nishino I. Dominant mutations in ORAI1 cause tubularaggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca2+ channels. Hum. Mol.
Genet. 24, 637-648 (2015).
Inamori KI, Willer T, Hara Y, Venzke D, Anderson ME, Clarke NF, Guicheney P, Bönnemann CG, Moore SA,Campbell KP. Endogenous Glucuronyltransferase Activity of LARGE or LARGE2 Required for Functional
Modification of α-dystroglycan in Cells and Tissues. J. Biol. Chem. 289, 28138-28148 (2014).
Inamori K, Yoshida-Moriguchi T, Hara Y, Anderson ME, Yu L, Campbell KP. Dystroglycan function requires
xylosyl- and glucuronyltransferase activities of LARGE. Science 335, 93-96 (2012).
Hara Y#, Kanagawa M#, Kunz S, Yoshida-Moriguchi T, Satz JS, Kobayashi YM, Zhu Z, Burden SJ, OldstoneMB, *Campbell KP. Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at
Thr-317/319 is required for laminin binding and arenavirus infection. Proc. Natl. Acad. Sci. USA. 108, 1742617431 (2011). (#: Co-first authors)
Hara Y#, Balci-Hayta B#, Yoshida-Moriguchi T, Kanagawa M, Beltrán-Valero de Bernabé D, Gündeşli H,Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, Talim B, Muntoni F, TopaloğluH, Dinçer P, *Campbell KP. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl.
J. Med. 364, 939-946 (2011). (#: Co-first authors)
Yamamoto S, Shimizu S, Kiyonaka S, Takahashi N, Wajima T, Hara Y, Negoro T, Hiroi T, Kiuchi Y, Okada T,Kaneko S, Lange I, Fleig A, Penner R, Nishi M, Takeshima H, Mori Y. TRPM2-mediated Ca2+ influx induces
chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat. Med. 14, 738-747(2008).
Yoshida T, Inoue R, Morii T, Takahashi N, Yamamoto S, Hara Y, Tominaga M, Shimizu S, Sato Y, Mori Y. Nitricoxide activates TRP channels by cysteine S-nitrosylation. Nat. Chem. Biol. 11, 596-607 (2006).
Togashi K, Hara Y, Tominaga T, Higashi T, Konishi Y, Mori Y, Tominaga M. TRPM2 activation by cyclic
ADP-ribose at body temperature is involved in insulin secretion. EMBO J. 25, 1804-1815 (2006).
Nishida M, Sugimoto K, Hara Y, Mori E, Morii T, Kurosaki T, and Mori Y. Amplification of receptor signaling
by Ca2+ entry-mediated translocation and activation of phospholipase Cγ2 in B lymphocytes. EMBO J, 22,4677-4688 (2003).
Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T, Yamada H, Shimizu S, Mori E, Kudoh J,Shimizu N, Kurose H, Okada Y, Imoto K, and Mori Y. LTRPC2 Ca2+-permeable channel activated by changes inredox status confers susceptibility to cell death. Mol. Cell, 9, 163-173 (2002).

Book Chapter
Hara Y, Campbell KP. Dystroglycan: An Extracellular Matrix Receptor That Links to the Cytoskeleton,
Glycoscience: Biol. Med. (Springer, invited book chapter), 1245-1251 (2014).